Experts in CHO and HEK-293.
How can we help you?
Cell line development SARS-CoV-2 trimeric spike proteins cGMP cell banking Rapid protein production Virus-like particle production Tox material productionFeatured
ExcellGene to Manufacture SARS-CoV-2 Trimeric Omicron Spike Protein, Optimized for Subunit Vaccine, Diagnostic and Drug Development
We announce an initiative for the mass production of the SARS-CoV-2 trimeric Omicron spike protein in CHO cells, which will help vaccine producers, diagnostic testing companies, and drug developers with optimal and abundant spike-protein material. This follows a similar initiative ExcellGene previously launched to meet demand for the SARS-CoV-2 trimeric Delta spike protein.
Additionally, the SARS-CoV-2 proteins section of our website has been updated with all current available spike variants, including Delta, Alpha, Beta and Wuhan.
Read the press release See all available spike proteinsNews
- Publication: Naming CHO Cells for Bio-manufacturing
- Twenty Years of Scientific Innovation at ExcellGene
- Video: From DNA to Therapeutic Protein in CHO Cells
- White Paper: Recombinant Proteins for Industrial versus Pharmaceutical Purposes: A Review of Process and Pricing
- New career opportunities available in cell culture and business development!
- Trimeric SARS-CoV-2 Spike Proteins Produced from CHO Cells in Bioreactors Are High-Quality Antigens (Summary)
- SARS-CoV-2 trimeric spike proteins, now available in grams.
- Subunit Vaccine Production in CHO cells: Development of an Efficacious Ebola Virus Vaccine Candidate
- White Paper: CHO Quasispecies – Implications for Manufacturing Processes More news items
Our services
Expect great science. It's in our DNA.
Our services in stable cell line development and recombinant protein manufacturing cover the value chain - from DNA construction and transfection to CHO and HEK process development, to large-scale protein production. Our cGMP compliant facility enables the generation of Master Cell Banks and Master Working Banks (MCB, MWB).
Cell line development
Early on in our development of the CHOExpress™ and HEKExpress-293™ systems, we were able to identify highly stable and robust cell lines for transfection, production and scale-up. Because of this, we can now develop cell lines in less than 5 months.
cGMP master cell banking
We provide the highest standard of quality at our Swissmedic inspected facility. Our flexible cGMP plant allows banking of cell cultures for clients that use an immortalized cell line for protein production.
Rapid protein production
Get up to 200 mg of protein in 3 weeks and up to 20 g of protein in 2 months. Our proprietary transient gene expression CHOExpress™ and HEKExpress-293™ cells have been optimized for rapid growth, efficient DNA uptake, high protein expression and high density in suspension cultures (> 30 million cells/mL).
Virus-like particle production
We provide optimization for multi-gene constructs, media optimizations for transfection and product generation. Our system uses no baculovirus and is therefore purely transfection based.
Tox material production
Have you been limited by not having enough materials to properly design your pre-clinical studies in animals? ExcellGene will help you plan experiments without the worry of running short of materials. We can deliver up to 500 grams of drug substance from a single batch.
Our technologies
A uniquely science-driven CDMO
Since 2001, ExcellGene has developed proprietary technologies and know-how that are key for the delivery of its clients’ projects on a timely manner and with a high degree of customization.
- CHO4Tx™ transfection kit: an easy to use in-house TGE protein expression kit;
- CHOexpress™ host cells: the fastest growing CHO host for biotech;
- HEKexpress™ host cells – a pioneering single-cell suspension host system for TGE and VLP production.
About us
We serve biotech clients worldwide
Our science-based approaches provide some of the fastest and most reliable results in the biotech industry. We have served over a hundred clients, including 6 of the top 10 firms in the biotechnology industry.
- Biotech 47%
- Big pharmaceutical 25%
- Academic 11%
- Other 18%